This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

Syngensys secures £1.8m seed fundraise with new commercial operations director appointment

Syngensys secures £1.8m seed fundraise with new commercial operations director appointment


National law firm Freeths has played a pivotal role in advising SynGenSys, a rapidly growing biotechnology spinout from the University of Sheffield, on its triumphant angel-led £1.8 million seed fundraise

This significant achievement coincides with the appointment of Dr. Andy Racher as the company's Commercial Operations Director.

The fundraise, facilitated with corporate finance advice from Translink, marks a milestone for SynGenSys. Specializing in the design and construction of synthetic genetic components to propel next-generation biomedicines and biomanufacturing processes, SynGenSys is poised for exponential growth with this infusion of capital.

Dr. Andy Racher brings with him over thirty years of invaluable experience in the biotechnology sector. His impressive track record includes holding various senior positions at Lonza Biologics, a prominent Contract Development and Manufacturing Organisation (CDMO). During his tenure at Lonza, Dr. Racher served in roles such as Director of R&D IP Strategy, Associate Director within the Future Technologies Group, Head of Process Development Sciences, Acting Head of Cell Culture Process Development, and Senior Principal Scientist of Cell Culture Process Development.

Freeths' Corporate Partner, Peter Crawford, expressed his satisfaction with the latest developments, stating, "Having recently advised on SynGenSys’ successful seed fundraise, it is great to see the company making real progress, and Andy’s appointment is fundamental to support that growth. I’m confident he will be a great addition to the team."

Dr. Andy Racher shared his enthusiasm for his new role, saying, "I am delighted to be joining the SynGenSys team at such an exciting time in the company's development, and I am looking forward to helping SynGenSys build out its market-facing commercial function."

Professor David James, co-founder and Chief Technology Officer of SynGenSys, expressed his satisfaction with Dr. Racher's appointment, remarking, "We are very pleased to have recruited someone of Andy's calibre to our team. His is the first of a number of appointments that the company is looking to make as we start to offer our products and services to customers across the world."

The synergy between SynGenSys' groundbreaking innovations and Dr. Andy Racher's wealth of experience promises a bright future for the company as it continues to revolutionize the biotechnology landscape.